Everomus 0.5 Tablet
Manufacturer
Zydus Cadila
Salt Composition
Everolimus (0.5mg)
Key Information
Short Description
Everomus 0.5 Tablet is used for the prevention of organ rejection in transplant patients and in combination with other medicines to treat cancers of breast, pancreas, lungs, and kidney.
Dosage Form
Tablet
Introduction
Everomus 0.5 Tablet is used for the prevention of organ rejection in transplant patients. It regulates the body's immune response, so the body can accept the new organ. It is also used in combination with other medicines to treat cancers of breast, pancreas, lungs, and kidney.
Directions for Use
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Everomus 0.5 Tablet may be taken with or without food but it is better to take it at a fixed time.
How it works
Everomus 0.5 Tablet suppresses the activity of body's immune system and prevents rejection of the transplanted organ.
Quick Tips
Everomus 0.5 Tablet is given for the treatment of certain cancers and to prevent organ transplant rejection. Everomus 0.5 Tablet may affect male or female fertility; consult your doctor if you are planning to have a child. Inform your doctor straight away if you think you are getting a sore throat or if you have a high temperature. While you are taking Everomus 0.5 Tablet do not take any vaccinations without talking to your doctor first. If you are having an operation or dental treatment, always tell the person carrying out the treatment that you are taking Everomus 0.5 Tablet. Do not drink grapefruit juice while you are taking this medicine.
Related Medicines
Evergraf 0.5mg Tablet
Advacan 0.5mg Tablet
Evercept 0.5mg Tablet
Certican 0.5 Tablet
Eversure 0.5 Tablet
Evercon 0.5mg Tablet
Natlimus 0.5mg Tablet
Lanolimus 0.5mg Tablet
Suregraft 0.5 Tablet
Everotas 0.5mg Tablet
Frequently asked questions
Does regular monitoring need to be done while using Everomus 0.5 Tablet?
Regular monitoring is necessary while taking Everomus 0.5 Tablet. Your doctor will advise blood tests to assess red blood cell, white blood cell, and platelet counts as these may decrease during treatment with Everomus 0.5 Tablet. Other blood tests will be required to check kidney function, liver function, blood glucose levels, and cholesterol levels.
What should I avoid while taking Everomus 0.5 Tablet?
Grapefruit or grapefruit juice should not be consumed while taking Everomus 0.5 Tablet because combining them may increase the drug's concentration in your blood, potentially leading to dangerous effects. Avoid live vaccinations and any potential contact with individuals who have received live vaccinations.
What is the most important information I should know about Everomus 0.5 Tablet?
Everomus 0.5 Tablet can cause serious side effects, including severe allergic reactions, angioedema (swelling of the tissues), and kidney failure, which may be life-threatening. Infection or lung-related complications such as breathing difficulties are also possible.
Is Everomus 0.5 Tablet a chemotherapy?
Everomus 0.5 Tablet is an anticancer medication. It belongs to the kinase inhibitor class of medicines. It works by reducing blood supply to the tumor, which slows down the growth and spread of cancer cells.
How is Everomus 0.5 Tablet administered?
Everomus 0.5 Tablet is typically taken once or twice daily with or without food. It should be swallowed whole with water, not crushed or chewed.
How long can I take Everomus 0.5 Tablet?
The duration of treatment with Everomus 0.5 Tablet is not fixed. It continues until clinical benefits are observed, or unacceptable toxicity or side effects occur.
How will I know if Everomus 0.5 Tablet is shrinking my brain tumor?
The effect of Everomus 0.5 Tablet on the size of your brain tumor can only be confirmed with regular brain scans as advised by your doctor, as part of your treatment plan.
Is Everomus 0.5 Tablet cytotoxic?
Yes, Everomus 0.5 Tablet exhibits cytotoxicity against human cancer cells of breast, stomach, prostate, and kidneys (renal cell carcinoma).
